Clinical Research Directory
Browse clinical research sites, groups, and studies.
Controlled Trial of Hydrogen Water as a Treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Sponsor: Fred Friedberg
Summary
This is a 16-week controlled treatment trial of an over-the -counter supplement, hydrogen water, for individuals with ME/CFS patients. An active treatment condition will be compared to a placebo-control condition. The study will also seek confirmation of heart rate variability (HRV) as a biomarker, that is, as a predictor of improvement vs. non-improvement to be assessed at treatment termination. The HRV biomarker hypothesis is based on a finding that High Frequency HRV (cardio-parasympathetic measure) biologically separated improvers and non-improvers in my previous ME/CFS observational study.
Official title: Randomized Controlled Trial of Moderate Dose Hydrogen Water as a Treatment for ME/CFS
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2026-08-15
Completion Date
2027-07
Last Updated
2026-08-07
Healthy Volunteers
No
Conditions
Interventions
Placebo condition
16 week intervention of magnesium pill without active ingredient of molecular hydrogen.
Molecular hydrogen produced by a metallic magnesium tablet, consumed 3x a day dissolved in water. Treatment duration is 16 weeks.
The 3 daily doses of molecular hydrogen scheduled for a 16 week intervention. This distinguishes it from the placebo comparator condition.
Locations (1)
Stony Brook University
Stony Brook, New York, United States